Rechallenge of Everolimus for Metastatic Renal Cell Carcinoma after Recovery from Grade 3 Interstitial Lung Disease : A Case Report

HANDLE Web Site Open Access

Bibliographic Information

Other Title
  • Grade3の間質性肺疾患を起こした転移性腎細胞癌に対しエベロリムスの再投与を施行した1例
  • Grade 3 ノ カンシツセイ ハイ シッカン オ オコシタ テンイセイジンサイボウガン ニ タイシ エベロリムス ノ サイトウヨ オ シコウ シタ 1レイ

Search this article

Abstract

We report a case of the rechallenge of everolimus for metastatic renal cell carcinoma (RCC) after successful recovery from grade 3 interstitial lung disease (ILD). A 76-year-old man with metastatic RCC developed grade 3 ILD one month after the initiation of everolimus therapy (10 mg/day). ILD subsided in 4 months after the withdrawal of everolimus and treatment with corticosteroids. Half dose (5 mg/day) of everolimus was rechallenged for 9 months until another grade 3 ILD developed. Everolimus kept the disease under control for 13 months including the discontinuation period.

Journal

  • Hinyokika Kiyo

    Hinyokika Kiyo 60 (1), 25-28, 2014-01

    泌尿器科紀要刊行会

Details 詳細情報について

Report a problem

Back to top